Managing Editor, In Vivo
Latest From Lucie Ellis-Taitt
Industry experts from Norstella, whose data and technologies support decision making from R&D through to market access, shared their worries going into 2024.
Serna Bio is using machine learning and RNA biology to create a platform for the discovery of small molecule modulators of RNA. The startup will seek fresh funding in 2024 and is on the hunt for creative biopharma partnerships.
The long-term success of TechBio is dependent upon the flow of investment and alliances with mature life sciences companies. This collaborative model has proven many times over to be an ideal framework to develop new treatments for patients.
Created by Steve Lehmann, director of venture operations at Portal Innovations, Stargaze is an artificial intelligence platform that maps the structure of biotechnology innovation and uses that knowledge to identify fruitful startups.
Cell and gene therapy is a young biopharma sector approaching adolescence. As more companies transition from R&D to commercialization, has it got the balance right on diversity in senior leadership?
Industry experts at the recent Sachs Biotech in Europe Forum discussed the renaissance in the cardiovascular and cardiometabolic markets, which are gaining momentum on the back of recent approvals, deal activity and new company launches.